Salem Norman, Eggersdorfer Manfred
aNutritional Lipids, DSM Nutritional Lipids, Columbia, Maryland, USA bNutrition Science & Advocacy, DSM Nutritional Products, Basel, Switzerland.
Curr Opin Clin Nutr Metab Care. 2015 Mar;18(2):147-54. doi: 10.1097/MCO.0000000000000145.
To delineate the available sources of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for human consumption and to determine if the available supply is capable of supplying the nutrient levels recommended by expert bodies.
There are converging opinions among experts, professional organizations and health professionals that a recommendation for a daily individual consumption of 500 mg of EPA/DHA would provide health benefits, and this translates to an annual human consumption of 1.3 million metric tons. Current human consumption of EPA/DHA is estimated to be only a small fraction of this amount and many people may suffer from suboptimal health as a result of low intake. EPA and DHA originate in the phytoplankton and are made available in the human food chain mainly through fish and other seafood.
The fish catch is not elastic and in fact has long since reached a plateau. Aquaculture has grown rapidly, but most of the fish oil produced is currently being used to support aquaculture feed and so this would appear to limit aquaculture growth - or at least the growth in availability of fish sources of EPA/DHA. Vegetable oil-derived alpha-linolenic acid, though relatively plentiful, is converted only at a trace level in humans to DHA and not very efficiently to EPA, and so cannot fill this gap. Microbial EPA/DHA production can in the future be increased, although this oil is likely to remain more expensive than fish oil. Plant sources of EPA and DHA have now been produced in the laboratory via transgenic means and will eventually clear regulatory hurdles for commercialization, but societal acceptance remains in question. The purpose of this review is to discuss the various sources of omega-3 fatty acids within the context of the potential world demand for these nutrients. In summary, it is concluded that fish and vegetable oil sources will not be adequate to meet future needs, but that algal oil and terrestrial plants modified genetically to produce EPA and DHA could provide for the increased world demand.
阐述可供人类食用的二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)的来源,并确定现有供应量是否能够满足专家机构推荐的营养素水平。
专家、专业组织和健康专家一致认为,建议每人每日摄入500毫克EPA/DHA将有益健康,这意味着人类每年的摄入量为130万吨。目前人类对EPA/DHA的摄入量估计仅为该数量的一小部分,许多人可能因摄入量低而健康状况欠佳。EPA和DHA起源于浮游植物,主要通过鱼类和其他海鲜进入人类食物链。
鱼类捕捞量缺乏弹性,实际上早已达到平稳状态。水产养殖发展迅速,但目前生产的大部分鱼油都用于支持水产养殖饲料,因此这似乎会限制水产养殖的增长——或者至少限制EPA/DHA鱼类来源的可获得量增长。植物油衍生的α-亚麻酸虽然相对丰富,但在人体内仅微量转化为DHA,转化为EPA的效率也不高,因此无法填补这一缺口。未来微生物生产EPA/DHA的量可以增加,不过这种油可能仍比鱼油更昂贵。现已通过转基因手段在实验室中生产出了EPA和DHA的植物来源,最终将清除商业化的监管障碍,但社会接受度仍存在疑问。本综述的目的是在这些营养素潜在的全球需求背景下讨论ω-3脂肪酸的各种来源。总之,得出的结论是鱼类和植物油来源不足以满足未来需求,但藻类油和经过基因改造以生产EPA和DHA的陆生植物可以满足全球不断增长的需求。